<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b216cb2c-ff72-4b54-9486-404a23092128"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MESNA INJECTION safely and effectively.  See full prescribing information for MESNA INJECTION.<br/>
      <br/>MESNA injection, for intravenous use<br/>Initial U.S. Approval: 1988
</title>
   <effectiveTime value="20250302"/>
   <setId root="2a2a526f-636b-7920-4261-6c626f612a2a"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080579617" root="1.3.6.1.4.1.519.1"/>
            <name>Sagent Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="b66098cf-aecb-4ed7-8816-e9990dcb0616"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250302"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="25021-201" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Mesna</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mesna</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NR7O1405Q9" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mesna</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VHD28S0H7F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>2-Mercaptoethanesulfonic Acid</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>edetate disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>benzyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="25021-201-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20101201"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="25021-201-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20101201"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20101201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA090913" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="78ec3ea3-3a28-4d6b-8207-e50d61ef638d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
</paragraph>
               </text>
               <effectiveTime value="20190321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (<linkHtml href="#s1">1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitation of Use:</content>
                        </paragraph>
                        <paragraph>Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (<linkHtml href="#s1">1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2">
                     <id root="52e40102-08ca-42c5-9c34-8afa669bfd6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitation of Use:</content>
                        </paragraph>
                        <paragraph>Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="6b64bed3-e11c-4c30-8763-f51606d8728a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20190321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mesna injection may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of mesna tablets as outlined below. The dosing schedule should be repeated on each day that ifosfamide is administered.  When the dosage of ifosfamide is adjusted, the ratio of mesna to ifosfamide should be maintained. (<linkHtml href="#s3">2</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>Intravenous Dosing Schedule:
</paragraph>
                        <table width="100%">
                           <col width="30.608%" align="left"/>
                           <col width="23.156%" align="left"/>
                           <col width="23.081%" align="left"/>
                           <col width="23.156%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="justify" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">0 Hours
</td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">4 Hours
</td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">8 Hours
</td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Ifosfamide
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.2 g/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Mesna injection
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Intravenous and Oral Dosing Schedule:
</paragraph>
                        <table width="100%">
                           <col width="30.608%" align="left"/>
                           <col width="23.156%" align="left"/>
                           <col width="23.081%" align="left"/>
                           <col width="23.156%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="justify" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">0 Hours
</td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">2 Hours
</td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">6 Hours
</td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Ifosfamide
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">1.2 g/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Mesna injection
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Mesna tablets
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">480 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">480 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria. (<linkHtml href="#s6">2.3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="72560471-cc0c-4cea-b97f-22e5a6ac180f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Intravenous Dosing
</title>
                     <text>
                        <paragraph>Mesna injection may be given on a fractionated dosing schedule of three bolus intravenous injections as outlined below.
</paragraph>
                        <paragraph>Mesna injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage weight by weight (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of mesna injection is 60% of the ifosfamide dose. The recommended dosing schedule is outlined below in <content styleCode="bold">
                              <linkHtml href="#t1">Table 1</linkHtml>
                           </content>.
</paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1.  Recommended Intravenous Dosing Schedule
</caption>
                           <col width="25.375%" align="left"/>
                           <col width="24.550%" align="left"/>
                           <col width="24.650%" align="left"/>
                           <col width="25.425%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>1</sup>The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is increased or decreased, the ratio of mesna to ifosfamide should be maintained.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">0 Hours</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">4 Hours</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">8 Hours</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Ifosfamide</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.2 g/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Mesna injection</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="f3d4f45c-a0f4-4860-86d6-075f59d6b4fb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Intravenous and Oral Dosing
</title>
                     <text>
                        <paragraph>Mesna injection may be given on a fractionated dosing schedule of a single bolus injection followed by two oral administrations of mesna tablets as outlined below.
</paragraph>
                        <paragraph>Mesna injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. Mesna tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of mesna is 100% of the ifosfamide dose. The recommended dosing schedule is outlined in <content styleCode="bold">
                              <linkHtml href="#t2">Table 2</linkHtml>
                           </content>.
</paragraph>
                        <table ID="t2" width="100%">
                           <caption>Table 2. Recommended Intravenous and Oral Dosing Schedule
</caption>
                           <col width="29.632%" align="left"/>
                           <col width="23.981%" align="left"/>
                           <col width="24.056%" align="left"/>
                           <col width="22.331%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>1</sup>The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is increased or decreased, the ratio of mesna to ifosfamide should be maintained.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">0 Hours</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">2 Hours</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">6 Hours</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Ifosfamide</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.2 g/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Mesna injection</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Mesna tablets</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">480 mg/m<sup>2</sup>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">480 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The efficacy and safety of this ratio of intravenous and oral mesna has not been established as being effective for daily doses of ifosfamide higher than 2 g/m<sup>2</sup>.
</paragraph>
                        <paragraph>Patients who vomit within two hours of taking oral mesna should repeat the dose or receive intravenous mesna injection.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="5f700ea0-7a8b-42d2-9af1-331376c99b93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Monitoring for Hematuria
</title>
                     <text>
                        <paragraph>Maintain adequate hydration and sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria. If severe hematuria develops when mesna injection is given according to the recommended dosage schedule, dosage reductions or discontinuation of ifosfamide therapy may be required.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="b0f889fd-2e4c-4cd3-af3e-aae52aa27fc4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation for Intravenous Administration and Stability
</title>
                     <effectiveTime value="20190321"/>
                     <component>
                        <section ID="s8">
                           <id root="6b0cffbb-0d75-444f-b2b4-ac5a021b5049"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation</content>
                              </paragraph>
                              <paragraph>Determine the volume of mesna injection for the intended dose.
</paragraph>
                              <paragraph>Dilute the volume of mesna injection for the dose in any of the following fluids to obtain a final concentration of 20 mg per mL:<br/>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>5% Dextrose Injection, USP
</item>
                                 <item>5% Dextrose and 0.2% Sodium Chloride Injection, USP
</item>
                                 <item>5% Dextrose and 0.33% Sodium Chloride Injection, USP
</item>
                                 <item>5% Dextrose and 0.45% Sodium Chloride Injection, USP
</item>
                                 <item>0.9% Sodium Chloride Injection, USP
</item>
                                 <item>Lactated Ringer's Injection, USP
</item>
                              </list>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s9">
                           <id root="9168c5e8-cbe7-471e-8466-7c5b760f7a54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Stability</content>
                              </paragraph>
                              <paragraph>The mesna injection multidose vials may be stored and used for up to 8 days after initial puncture.
</paragraph>
                              <paragraph>Store diluted solutions at 25°C (77°F). Use diluted solutions within 24 hours.
</paragraph>
                              <paragraph>Do not mix mesna injection with epirubicin, cyclophosphamide, cisplatin, carboplatin, and nitrogen mustard.
</paragraph>
                              <paragraph>The benzyl alcohol contained in mesna injection vials can reduce the stability of ifosfamide. Ifosfamide and mesna injection may be mixed in the same bag provided the final concentration of ifosfamide does not exceed 50 mg per mL. Higher concentrations of ifosfamide may not be compatible with mesna injection and may reduce the stability of ifosfamide.
</paragraph>
                              <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Any solutions which are discolored, hazy, or contain visible particulate matter should not be used.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="c2906180-547d-4358-aaf0-f38d6b21ecaa"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Mesna Injection: 1 gram Multi-Dose Vial, 100 mg per mL
</item>
                  </list>
               </text>
               <effectiveTime value="20190321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Mesna Injection: 1 gram (100 mg per mL) Multi-Dose vials (<linkHtml href="#s10">3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="57562045-2f80-4a0e-ba83-02c45d863ee1"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>Mesna is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.1</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20190321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Known hypersensitivity to mesna or to any of the excipients in mesna, including benzyl alcohol. (<linkHtml href="#s11">4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="c9b84a76-08b1-4452-95a5-401ee6aea666"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20210114"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity reactions: Anaphylactic reactions have been reported. Less severe hypersensitivity reactions may also occur. Monitor patients. If a reaction occurs, discontinue mesna and provide supportive care. (<linkHtml href="#s13">5.1</linkHtml>)
</item>
                           <item>Dermatologic toxicity: Skin rash with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis have occurred. Skin rash, urticaria, and angioedema have also been seen. Monitor patients. If a reaction occurs, discontinue mesna and provide supportive care. (<linkHtml href="#s14">5.2</linkHtml>)
</item>
                           <item>Benzyl alcohol toxicity: Serious and fatal adverse reactions can occur in premature neonates and low-birth weight infants treated with benzyl alcohol-preserved drugs, including mesna injection. Avoid use in premature neonates and low-birth weight infants. (<linkHtml href="#s15">5.3</linkHtml>)
</item>
                           <item>Laboratory test alterations: False positive tests for urinary ketones and interference with enzymatic CPK activity tests have been seen. (<linkHtml href="#s16">5.4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s13">
                     <id root="a51e8df1-ee16-46e4-a70f-d5bfbff25cdb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>Mesna may cause systemic hypersensitivity reactions, including anaphylaxis. These reactions may include fever, cardiovascular symptoms (hypotension, tachycardia), acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema, laboratory signs of disseminated intravascular coagulation, hematological abnormalities, increased liver enzymes, nausea, vomiting, arthralgia, and myalgia. These reactions may occur with the first exposure or after several months of exposure. Monitor for signs or symptoms. Discontinue mesna and provide supportive care.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="f2eb60b4-0b5a-4c33-9934-1286a97293fc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Dermatologic Toxicity
</title>
                     <text>
                        <paragraph>Drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions, consistent with Stevens-Johnson syndrome or toxic epidermal necrolysis have occurred. Mesna may cause skin and mucosal reactions characterized by urticaria, rash, erythema, pruritus, burning sensation, angioedema, periorbital edema, flushing and stomatitis. These reactions may occur with the first exposure or after several months of exposure. Discontinue mesna and provide supportive care.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="52b53141-31c9-4124-bc1b-8f85330369f2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Benzyl Alcohol Toxicity
</title>
                     <text>
                        <paragraph>Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and low-birth weight infants who received benzyl alcohol dosages of 99 to 234 mg/kg/day (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Symptoms associated with “gasping syndrome” and other potential adverse reactions include gradual neurological deterioration, seizures, intracranial hemorrhage, hematological abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Premature neonates and low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Mesna injection contains 10.4 mg/mL of the preservative benzyl alcohol. Avoid use of mesna injection in premature neonates and low-birth weight infants. Mesna tablets do not contain benzyl alcohol <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s37">8.4</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="4e36917f-ed92-4c86-9b1b-23ad6248b525"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>5.4 Laboratory Test Interferences
</title>
                     <effectiveTime value="20190321"/>
                     <component>
                        <section ID="s17">
                           <id root="e5c8ffd3-bcdf-4b6c-a94f-aab7eb822a5a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">False-Positive Urine Tests for Ketone Bodies</content>
                              </paragraph>
                              <paragraph>A false positive test for urinary ketones may arise in patients treated with mesna when using nitroprusside sodium-based urine tests (including dipstick tests). The addition of glacial acetic acid can be used to differentiate between a false positive result (cherry-red color that fades) and a true positive result (red-violet color that intensifies).
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s18">
                           <id root="9cee0b49-78bc-4784-97fd-716c276cfbb7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">False-Negative Tests for Enzymatic CPK Activity</content>
                              </paragraph>
                              <paragraph>Mesna may interfere with enzymatic creatinine phosphokinase (CPK) activity tests that use a thiol compound (e.g., N-acetylcysteine) for CPK reactivation. This may result in a falsely low CPK level.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s19">
                           <id root="6d6fec3e-27a5-45eb-9dea-d8da27fef7ae"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">False-Positive Tests for Ascorbic Acid</content>
                              </paragraph>
                              <paragraph>Mesna may cause false-positive reactions in Tillman's reagent-based urine screening tests for ascorbic acid.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="c03b9caf-1a6f-4da1-b974-92e2eaf4ca0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Use in Patients with a History of Adverse Reactions to Thiol Compounds
</title>
                     <text>
                        <paragraph>Mesna is a thiol compound, i.e., a sulfhydryl (SH) group-containing organic compound. Hypersensitivity reactions to mesna and to amifostine, another thiol compound, have been reported. It is not clear whether patients who experienced an adverse reaction to a thiol compound are at increased risk for a hypersensitivity reaction to mesna.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="3695b86b-a37f-4bc7-9bef-931f3268b5f7"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following are discussed in more detail in other sections of the labeling.
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.1</linkHtml>)]</content>
                     </item>
                     <item>Dermatological Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.2</linkHtml>)]</content>
                     </item>
                     <item>Benzyl Alcohol Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.3</linkHtml>)]</content>
                     </item>
                     <item>Laboratory Test Interferences <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.4</linkHtml>)]</content>
                     </item>
                     <item>Use in Patients with a History of Adverse Reactions to Thiol Compounds <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.5</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (&gt; 10%) when mesna is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence. (<linkHtml href="#s22">6.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold underline">www.fda.gov/medwatch</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s22">
                     <id root="885977e2-3a5e-4397-86b9-73f8d1183de5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                        <paragraph>Mesna adverse reaction data are available from four Phase 1 studies in which single intravenous doses of 600 to 1200 mg mesna injection without concurrent chemotherapy were administered to a total of 53 healthy volunteers. The most frequently reported side effects (observed in two or more healthy volunteers) for healthy volunteers receiving single doses of mesna injection alone were headache, injection site reactions, flushing, dizziness, nausea, vomiting, somnolence, diarrhea, anorexia, fever, pharyngitis, hyperesthesia, influenza-like symptoms, and coughing. In two Phase 1 multiple-dose studies where healthy volunteers received mesna tablets alone or intravenous mesna followed by repeated doses of mesna tablets, flatulence and rhinitis were reported. In addition, constipation was reported by healthy volunteers who had received repeated doses of intravenous mesna.
</paragraph>
                        <paragraph>Additional adverse reactions in healthy volunteers receiving mesna alone included injection site reactions, abdominal pain/colic, epigastric pain/burning, mucosal irritation, lightheadedness, back pain, arthralgia, myalgia, conjunctivitis, nasal congestion, rigors, paresthesia, photophobia, fatigue, lymphadenopathy, extremity pain, malaise, chest pain, dysuria, pleuritic pain, dry mouth, dyspnea, and hyperhidrosis. In healthy volunteers, mesna was commonly associated with a rapid (within 24 hours) decrease in lymphocyte count, which was generally reversible within one week of administration.
</paragraph>
                        <paragraph>Because mesna is used in combination with ifosfamide or ifosfamide-containing chemotherapy regimens, it is difficult to distinguish the adverse reactions which may be due to mesna from those caused by the concomitantly administered cytotoxic agents.
</paragraph>
                        <paragraph>Adverse reactions reasonably associated with mesna administered intravenously and orally in four controlled studies in which patients received ifosfamide or ifosfamide-containing regimens are presented in <content styleCode="bold">
                              <linkHtml href="#t3">Table 3</linkHtml>
                           </content>.
</paragraph>
                        <table ID="t3" width="100%">
                           <caption>Table 3: Adverse Reactions in ≥5% of Patients Receiving Mesna in combination with Ifosfamide-containing Regimens
</caption>
                           <col width="23.833%" align="left"/>
                           <col width="43.067%" align="left"/>
                           <col width="33.100%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <content styleCode="bold">
                                          <sup>1</sup>
                                       </content>Intravenous dosing of ifosfamide and mesna followed by either intravenous or oral doses of mesna according to the applicable dosage schedule <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s3">2</linkHtml>)].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Mesna Regimen</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Intravenous-Intravenous-Intravenous</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Intravenous-Oral-Oral</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">N exposed
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">119 (100.0%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">119 (100%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Incidence of AEs
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">101 (84.9%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">106 (89.1%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">65 (54.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">64 (53.8)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Vomiting
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">35 (29.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">45 (37.8)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Constipation
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">28 (23.5)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 (17.6)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Leukopenia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">25 (21.0)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 (17.6)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fatigue
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">24 (20.2)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">24 (20.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fever
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">24 (20.2)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">18 (15.1)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Anorexia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 (17.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">19 (16.0)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Thrombocytopenia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 (17.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">16 (13.4)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Anemia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">20 (16.8)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 (17.6)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Granulocytopenia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">16 (13.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">15 (12.6)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Asthenia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">15 (12.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">21 (17.6)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Abdominal Pain
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">14 (11.8)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">18 (15.1)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Alopecia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">12 (10.1)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">13 (10.9)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspnea
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">11 (9.2)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">11 (9.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Chest Pain
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (8.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">11 (9.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypokalemia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (8.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">11 (9.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (7.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">17 (14.3)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dizziness
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (7.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (4.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (7.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">13 (10.9)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pain
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (7.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (8.4)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Sweating Increased
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (7.6)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1.7)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Back Pain
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hematuria
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7 (5.9)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Injection Site Reaction
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (8.4)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Edema
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">9 (7.6)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Edema Peripheral
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Somnolence
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">12 (10.1)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Anxiety
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7 (5.9)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (3.4)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Confusion
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7 (5.9)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Face Edema
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (4.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Insomnia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">11 (9.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Coughing
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">5 (4.2)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10 (8.4)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspepsia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (3.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypotension
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (3.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pallor
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">4 (3.4)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dehydration
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">3 (2.5)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7 (5.9)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pneumonia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">2 (1.7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8 (6.7)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Tachycardia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7 (5.9)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Flushing
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1 (0.8)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6 (5.0)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="28cba97f-ea02-48cb-9827-54205de594fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience
</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported in the postmarketing experience of patients receiving mesna in combination with ifosfamide or similar drugs, making it difficult to distinguish the adverse reactions which may be due to mesna from those caused by the concomitantly administered cytotoxic agents. Because these reactions are reported from a population of unknown size, precise estimates of frequency cannot be made.
</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular</content>: Hypertension <br/>
                           <content styleCode="italics">Gastrointestinal</content>: Dysgeusia <br/>
                           <content styleCode="italics">Hepatobiliary</content>: Hepatitis <br/>
                           <content styleCode="italics">Nervous System</content>: Convulsion <br/>
                           <content styleCode="italics">Respiratory</content>: Hemoptysis
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="736d0f11-50af-43c1-94f7-95eeba7d7792"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <text>
                  <paragraph>No clinical drug interaction studies have been conducted with mesna.
</paragraph>
               </text>
               <effectiveTime value="20190321"/>
            </section>
         </component>
         <component>
            <section ID="s25">
               <id root="70809d5e-0689-42c4-a275-a844781d9c17"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20241031"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy: Mesna in combination with ifosfamide can cause fetal harm. Advise patients of potential risk to a fetus. (<linkHtml href="#s26">8.1</linkHtml>)
</item>
                           <item>Lactation: Do not breastfeed. (<linkHtml href="#s30">8.2</linkHtml>)
</item>
                           <item>Females and Males of Reproductive Potential: Advise patients to use effective contraception. Verify pregnancy status prior to initiation of mesna in combination with ifosfamide. (<linkHtml href="#s32">8.3</linkHtml>)
</item>
                           <item>Pediatric use: In premature neonates and low-birth weight infants, avoid use of benzyl alcohol–containing solutions. (<linkHtml href="#s37">8.4</linkHtml>)
</item>
                           <item>Geriatric use: Dose selection should be cautious. (<linkHtml href="#s38">8.5</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s26">
                     <id root="acddefed-d407-4b20-be28-3a2e0b871b32"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20241031"/>
                     <component>
                        <section ID="s27">
                           <id root="db25c140-3e54-43dc-96e8-0369de2a9b44"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Mesna is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm when administered to a pregnant woman. Refer to the ifosfamide prescribing information for more information on use during pregnancy.
</paragraph>
                              <paragraph>Mesna injection contains the preservative benzyl alcohol. Because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#s37">8.4</linkHtml>)].</content>
                              </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s28">
                           <id root="130e4973-cddc-419d-8850-1bef3ebd3c99"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241031"/>
                           <component>
                              <section ID="s29">
                                 <id root="927f4e41-e1ca-4206-a56e-7c3ac3dbe843"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Mesna is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm including embryo-fetal lethality. Refer to the ifosfamide prescribing information for more information on use during pregnancy.
</paragraph>
                                    <paragraph>In embryo-fetal development studies, oral administration of mesna to pregnant rats (500, 1,000, 1,500, and 2,000 mg/kg) and rabbits (500 and 1,000 mg/kg) during the period of organogenesis revealed no adverse developmental outcomes at doses approximately 10 times the maximum recommended total daily human equivalent dose based on body surface area.
</paragraph>
                                 </text>
                                 <effectiveTime value="20241031"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s30">
                     <id root="9577701e-40e2-4b69-ae10-727ea2eb6808"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20190321"/>
                     <component>
                        <section ID="s31">
                           <id root="18c77979-ca43-47cc-8dd4-b12238fa4c16"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Mesna is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide is excreted in breast milk. Refer to the ifosfamide prescribing information for more information on use during lactation. There are no data on the presence of mesna in human or animal milk, the effect on the breastfed child, or the effect on milk production.
</paragraph>
                              <paragraph>Mesna injection contains the preservative benzyl alcohol. Because benzyl alcohol is rapidly metabolized by a lactating woman, benzyl alcohol exposure in the breastfed infant is unlikely. However, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#s37">8.4</linkHtml>)]</content>.
</paragraph>
                              <paragraph>Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment and for 1 week after the last dose of mesna or ifosfamide.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="15668b76-43af-4909-9490-b894a5fcc2a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <text>
                        <paragraph>Mesna is used in combination with ifosfamide or other cytotoxic agents. Ifosfamide can cause fetal harm when administered to a pregnant woman. Refer to the ifosfamide prescribing information for more information on contraception and effects on fertility.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                     <component>
                        <section ID="s33">
                           <id root="6c18b3e8-97cb-4908-a0a3-6cf72db31e61"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiation of mesna in combination with ifosfamide.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s34">
                           <id root="d51f8c4b-54da-483e-a6ec-d96d8c9f9da3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                           <component>
                              <section ID="s35">
                                 <id root="e7890579-4ef0-4af8-9a00-8c632b176249"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with mesna in combination with ifosfamide and for 6 months after the last dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190321"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s36">
                                 <id root="7b8e2397-b096-45ab-9e60-00a3e2d5291f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with mesna in combination with ifosfamide and for 3 months after the last dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190321"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="37881a7c-974c-4545-991f-92c57d29ea89"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>Mesna injection contains the preservative benzyl alcohol which has been associated with serious adverse reactions and death when administered intravenously to premature neonates and low-birth weight infants. Avoid use of mesna injection in premature neonates and low-birth weight infants <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s38">
                     <id root="705dcd27-8523-46db-94b6-65b5af46a6d5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Clinical studies of mesna did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The ratio of ifosfamide to mesna should remain unchanged.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s39">
                     <id root="4fc1c38a-223a-4c2e-ab01-478e49133cb2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Use in Patients with Renal Impairment
</title>
                     <text>
                        <paragraph>No clinical studies were conducted to evaluate the effect of renal impairment on the pharmacokinetics of mesna.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s40">
                     <id root="f0c1ce99-c57e-4479-8b3a-ced71de3d11f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Use in Patients with Hepatic Impairment
</title>
                     <text>
                        <paragraph>No clinical studies were conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of mesna.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s41">
               <id root="9962bf93-5e31-484e-8b8b-d460420dcf7a"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <text>
                  <paragraph>There is no known antidote for mesna.
</paragraph>
                  <paragraph>In a clinical trial, 11 patients received intravenous mesna 10 mg/kg to 66 mg/kg per day for 3 to 5 days. Patients also received ifosfamide or cyclophosphamide. Adverse reactions included nausea, vomiting, diarrhea and fever. An increased rate of these adverse reactions has also been found in oxazaphosphorine-treated patients receiving ≥80 mg mesna per kg per day intravenously compared with patients receiving lower doses or hydration treatment only.
</paragraph>
                  <paragraph>Postmarketing, administration of 4.5 grams to 6.9 grams of mesna resulted in hypersensitivity reactions including mild hypotension, shortness of breath, asthma exacerbation, rash, and flushing.
</paragraph>
               </text>
               <effectiveTime value="20241031"/>
            </section>
         </component>
         <component>
            <section ID="s42">
               <id root="2d395af7-7c23-41cf-8a1d-89f56711146e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Mesna is a sterile, nonpyrogenic, aqueous detoxifying agent to inhibit the hemorrhagic cystitis induced by ifosfamide. The active ingredient, mesna, is a synthetic sulfhydryl compound designated as sodium-2-mercaptoethane sulfonate with a molecular formula of C<sub>2</sub>H<sub>5</sub>NaO<sub>3</sub>S<sub>2</sub> and a molecular weight of 164.18. Its structural formula is as follows:
</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Mesna Injection is a sterile, nonpyrogenic, aqueous solution of colorless to light pink appearance in clear glass multidose vials for intravenous administration. Mesna Injection contains 100 mg per mL mesna, 0.25 mg per mL edetate disodium, sodium hydroxide for pH adjustment and qs with Water for Injection. Mesna Injection multidose vials also contain 10.4 mg per mL of benzyl alcohol as a preservative. The solution has a pH range of 6.5 to 7.4.
</paragraph>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mes01-0009-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s43">
               <id root="ce06b3f7-c813-4670-a54a-4a8d306a3293"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20210114"/>
               <component>
                  <section ID="s44">
                     <id root="6523c8b8-0c1a-4366-8b07-8df6fe43a1a8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic metabolites and inhibits their effects on the bladder.
</paragraph>
                     </text>
                     <effectiveTime value="20210114"/>
                  </section>
               </component>
               <component>
                  <section ID="s45">
                     <id root="7862f217-1e9d-45c5-9e88-0e95e7eee760"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <effectiveTime value="20190321"/>
                     <component>
                        <section ID="s46">
                           <id root="4357fead-cd54-43e3-9109-a19980642ab3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Absorption</content>
                              </paragraph>
                              <paragraph>Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively. Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
</paragraph>
                              <paragraph>Food does not affect the urinary availability of orally administered mesna.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s47">
                           <id root="769a943f-bf29-441f-9071-b9716f54afb6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Distribution</content>
                              </paragraph>
                              <paragraph>Mean apparent volume of distribution (V<sub>d</sub>) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s48">
                           <id root="0f0bba3c-1cf7-4153-a06d-b3b9fbc0c709"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>Analogous to the physiological cysteine-cystine system, mesna is rapidly oxidized to its major metabolite, mesna disulfide (dimesna). Plasma concentrations of mesna exceed those of dimesna after oral or intravenous administration.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s49">
                           <id root="38bd4267-b5af-4a93-a94e-f346b9db669d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Excretion</content>
                              </paragraph>
                              <paragraph>Following intravenous administration of a single 800 mg dose, approximately 32% and 33% of the administered dose was eliminated in the urine in 24 hours as mesna and dimesna, respectively. Mean plasma elimination half-lives of mesna and dimesna are 0.36 hours and 1.17 hours, respectively. Mesna has a plasma clearance of 1.23 L/h/kg.
</paragraph>
                           </text>
                           <effectiveTime value="20190321"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s50">
               <id root="19092331-a2b4-412f-b5b6-628c8e032c31"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="s51">
                     <id root="0a23362e-0f8c-4269-8a69-d194968a9f6b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>No long-term studies in animals have been performed to evaluate the carcinogenic potential of mesna.
</paragraph>
                        <paragraph>Mesna was not genotoxic in the <content styleCode="italics">in vitro</content> Ames bacterial mutagenicity assay, the <content styleCode="italics">in vitro</content> mammalian lymphocyte chromosomal aberration assay or the <content styleCode="italics">in vivo</content> mouse micronucleus assay.
</paragraph>
                        <paragraph>No studies on male or female fertility were conducted. No signs of male or female reproductive organ toxicity were seen in 6-month oral rat studies (≤2,000 mg/kg/day) or 29-week oral dog studies (520 mg/kg/day) at doses approximately 10-fold higher than the maximum recommended human dose on a body surface area basis.
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="6d6f45e6-744d-4416-a42f-f96334e76651"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20190321"/>
               <component>
                  <section ID="s53">
                     <id root="c01067df-88e3-41c6-a329-12a6e2864f1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Intravenous Mesna
</title>
                     <text>
                        <paragraph>Hemorrhagic cystitis produced by ifosfamide is dose dependent (<content styleCode="bold">
                              <linkHtml href="#t4">Table 4</linkHtml>
                           </content>). At a dose of 1.2 g/m<sup>2</sup> ifosfamide administered daily for 5 days, 16 to 26% of the patients who received conventional uroprophylaxis (high fluid intake, alkalinization of the urine, and the administration of diuretics) developed hematuria (&gt;50 RBC per hpf or macrohematuria) (Studies 1, 2, and 3). In contrast, none of the patients who received mesna injection together with this dose of ifosfamide developed hematuria (Studies 3 and 4). In two randomized studies, (Studies 5 and 6), higher doses of ifosfamide, from 2 g/m<sup>2</sup> to 4 g/m<sup>2</sup> administered for 3 to 5 days, produced hematuria in 31 to 100% of the patients. When mesna was administered together with these doses of ifosfamide, the incidence of hematuria was less than 7%.
</paragraph>
                        <table ID="t4" width="100%">
                           <caption>Table 4. Percent of Mesna Patients Developing Hematuria (≥50 RBC/hpf or macrohematuria)
</caption>
                           <col width="28.176%" align="left"/>
                           <col width="34.512%" align="left"/>
                           <col width="37.312%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                                    <paragraph styleCode="footnote">*Ifosfamide dose 1.2 g/m<sup>2</sup> d x 5
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <paragraph styleCode="footnote">†Ifosfamide dose 2 g/m<sup>2</sup> to 4 g/m<sup>2</sup> d x 3 to 5
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Study</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Conventional Uroprophylaxis</content>
                                    <br/>
                                    <content styleCode="bold">(number of patients)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Standard Mesna Intravenous</content>
                                    <br/>
                                    <content styleCode="bold">Regimen (number of patients)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Uncontrolled Studies*</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Study 1
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">16% (7/44)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Study 2
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">26% (11/43)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Study 3
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">18% (7/38)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0% (0/21)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Study 4
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0% (0/32)
</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Controlled Studies</content>
                                    <content styleCode="bold">
                                       <sup>†</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Study 5
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">31% (14/46)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">6% (3/46)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Study 6
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">100% (7/7)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">0% (0/8)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s54">
               <id root="874b25c1-44eb-4d3e-a83f-b406e7dac20a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>Mesna Injection is supplied as follows:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="18.994%" align="left"/>
                     <col width="56.748%" align="left"/>
                     <col width="24.259%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">NDC</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Mesna Injection (100 mg per mL)</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Package Factor</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">25021-201-10
</td>
                           <td align="left" valign="top">1 gram per 10 mL Multi-Dose Vial
</td>
                           <td align="left" valign="top">1 vial per carton
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">25021-201-11
</td>
                           <td align="left" valign="top">1 gram per 10 mL Multi-Dose Vial
</td>
                           <td align="left" valign="top">10 vials per carton
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20190321"/>
               <component>
                  <section ID="s55">
                     <id root="730163e8-d4e7-4ed4-8263-b6aef6f93dab"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage Conditions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Sterile, Nonpyrogenic. <br/>The container closure is not made with natural rubber latex.</content>
                        </paragraph>
                        <paragraph>If Mesna Injection is co-administered with ifosfamide, refer to the ifosfamide prescribing information for safe handling instructions.
</paragraph>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s56">
               <id root="a845ec57-3fa8-4a78-8f99-524f9d54abad"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <effectiveTime value="20241031"/>
               <component>
                  <section ID="s57">
                     <id root="fa7de50e-02d5-452a-9a84-4007acb751c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise the patient to discontinue mesna and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction, including systemic anaphylactic reactions occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.1</linkHtml>)].</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Hemorrhagic Cystitis</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Mesna does not prevent hemorrhagic cystitis in all patients nor does it prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide. Advise the patient to report to their healthcare provider if his/her urine has turned a pink or red color <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.3</linkHtml>)].</content>
                           </item>
                           <item>Advise the patient to drink 1 to 2 liters of fluid each day during mesna therapy <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.3</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="b35d57d0-f000-4a0c-80f8-ae5199abbe16"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Dermatologic Toxicity</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise the patient that Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions have occurred with mesna. Advise the patient to report to their healthcare provider if signs and symptoms of these syndromes occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.2</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s59">
                     <id root="862baafa-68eb-4557-8ea3-3f913ef169b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Benzyl Alcohol Toxicity</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise patients that serious adverse reactions are associated with the benzyl alcohol found in mesna and other medications in premature neonates and low-birth weight infants <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#s37">8.4</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s60">
                     <id root="f1ab2802-9e97-4021-858e-83c804bf8069"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Mesna is used in combination with ifosfamide. Ifosfamide or other cytotoxic agents can cause fetal harm when administered to a pregnant woman. Inform female patients of the risk to a fetus and potential loss of the pregnancy. Advise females to inform their healthcare provider if they are pregnant or become pregnant <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s26">8.1</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s61">
                     <id root="e3ee285b-e703-4876-ac70-290fcbc52920"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Contraception</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise females of reproductive potential to use effective contraception during treatment with mesna in combination with ifosamide and for 6 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s32">8.3</linkHtml>)]</content>.
</item>
                           <item>Advise male patients with female partners of reproductive potential to use effective contraception during treatment with mesna in combination with ifosamide and for 3 months after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s32">8.3</linkHtml>)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190321"/>
                  </section>
               </component>
               <component>
                  <section ID="s62">
                     <id root="e50a1353-78cb-49f7-8af8-2f23e7b8573d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Lactation</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise lactating women not to breastfeed during treatment with mesna or ifosfamide and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s30">8.2</linkHtml>)]</content>.
</item>
                        </list>
                        <paragraph>sagent<sup>®</sup>
                           <br/>Mfd. for SAGENT Pharmaceuticals<br/>Schaumburg, IL 60173 (USA) <br/>Made in India<br/>©2024 Sagent Pharmaceuticals
</paragraph>
                        <paragraph>Revised: October 2024
</paragraph>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s63">
               <id root="5005dbf2-3c47-4341-b5e7-9a0b21e15111"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</paragraph>
                  <paragraph>NDC 25021-201-10
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Mesna Injection
</paragraph>
                  <paragraph>1 gram per 10 mL
</paragraph>
                  <paragraph>(100 mg per mL)
</paragraph>
                  <paragraph>For Intravenous Use
</paragraph>
                  <paragraph>10 mL Multi-Dose Vial
</paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
               </text>
               <effectiveTime value="20241031"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="mes01-0009-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>